ABCL
AbCellera Biologics Inc. NASDAQ Listed Dec 11, 2020$12.73
+9.08%
vs $11.67
Mkt Cap $3.8B
52w Low $2.78
100.0% of range
52w High $12.73
50d MA $9.00
200d MA $5.45
P/E (TTM)
-23.6x
EV/EBITDA
—
P/B
3.3x
Debt/Equity
0.1x
ROE
-15.1%
P/FCF
-21.8x
RSI (14)
53.30
ATR (14)
$0.67
Beta
0.85
50d MA
$9.00
200d MA
$5.45
Avg Volume
8.3M
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
2215 Yukon Street · Vancouver, BC V5Y 0A1 · CA
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 5, 2026 | AMC | -0.14 | -0.18 | -24.7% | 5.92 | -2.2% | +10.3% | +6.1% | +34.8% | +4.5% | +6.1% | — |
| May 11, 2026 | AMC | -0.22 | -0.14 | +36.4% | 5.25 | -9.3% | -5.7% | -3.6% | -7.8% | -7.0% | +1.7% | — |
| Feb 24, 2026 | AMC | -0.18 | -0.03 | +83.3% | 3.22 | +4.3% | -0.9% | +12.5% | +0.6% | +5.8% | -2.9% | — |
| Nov 6, 2025 | AMC | -0.17 | -0.19 | -11.8% | 4.53 | -16.1% | -13.7% | +3.1% | -0.5% | -1.0% | -8.8% | — |
| Aug 7, 2025 | AMC | -0.17 | -0.12 | +29.4% | 4.24 | +13.7% | +0.2% | +5.9% | -5.1% | +7.3% | -1.7% | — |
| May 8, 2025 | AMC | -0.17 | -0.15 | +11.8% | 2.01 | +2.5% | +1.0% | +1.5% | +1.9% | -2.4% | -1.5% | — |
| Feb 27, 2025 | AMC | -0.15 | -0.11 | +26.7% | 2.92 | -6.8% | -11.3% | -8.9% | -0.8% | +2.1% | -0.4% | — |
| Nov 4, 2024 | AMC | -0.14 | -0.17 | -21.4% | 2.89 | -13.5% | -5.9% | +1.5% | -1.4% | -0.7% | +16.7% | — |
| Aug 6, 2024 | AMC | -0.15 | -0.13 | +13.3% | 2.85 | -3.5% | -7.7% | +5.3% | -3.2% | -1.5% | +1.1% | — |
| May 7, 2024 | AMC | -0.16 | -0.14 | +12.5% | 4.04 | +0.0% | -5.0% | +2.9% | -3.0% | +0.5% | -0.8% | — |
| Feb 20, 2024 | AMC | -0.14 | -0.17 | -21.4% | 5.31 | -1.1% | -9.4% | +0.8% | +0.4% | +1.6% | +3.4% | — |
| Nov 2, 2023 | AMC | -0.14 | -0.10 | +28.6% | 4.43 | -10.4% | +6.1% | -4.8% | -1.7% | -5.0% | -3.3% | — |
| Aug 3, 2023 | AMC | -0.13 | -0.11 | +15.4% | 6.97 | -6.5% | -13.3% | -3.1% | +0.7% | +2.2% | -2.3% | — |
| May 4, 2023 | AMC | -0.12 | -0.14 | -16.7% | 6.61 | -3.0% | -9.4% | -4.7% | -0.9% | +4.1% | -2.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jul 7 | The Benchmark Company | Upgrade | Hold → Buy | $11 | $7.87 | $8.33 | +5.8% | -2.3% | -7.7% | +2.7% | -6.7% | -4.1% |
| May 5 | Cantor Fitzgerald | Initiates | Overweight | $7 | $4.59 | $5.05 | +10.0% | +1.5% | +8.2% | -4.4% | +8.7% | +0.2% |
| Nov 7 | Leerink Partners | Downgrade | Outperform → Market Perform | — | $4.53 | $3.80 | -16.1% | -13.7% | +3.1% | -0.5% | -1.0% | -8.8% |
| Aug 8 | Stifel | Maintains | Buy → Buy | — | $4.24 | $4.82 | +13.7% | +0.2% | +5.9% | -5.1% | +7.3% | -1.7% |
| Jul 14 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $4.01 | $4.01 | +0.0% | +5.7% | -7.1% | +3.0% | -3.9% | +14.9% |
| May 16 | Truist | Maintains | Buy → Buy | — | $2.02 | $2.03 | +0.5% | +0.5% | -0.5% | +3.5% | -4.8% | +0.5% |
| May 9 | Stifel | Maintains | Buy → Buy | — | $2.01 | $2.06 | +2.5% | +1.0% | +1.5% | +1.9% | -2.4% | -1.5% |
| Apr 16 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $2.43 | $2.45 | +0.8% | -1.6% | +1.3% | +1.2% | +2.9% | +0.4% |
| Mar 3 | Benchmark | Maintains | Hold → Hold | — | $2.59 | $2.61 | +0.8% | -8.9% | -0.8% | +2.1% | -0.4% | -2.1% |
| Feb 28 | Stifel | Maintains | Buy → Buy | — | $2.92 | $2.72 | -6.8% | -11.3% | -8.9% | -0.8% | +2.1% | -0.4% |
| Jan 8 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $3.28 | $3.26 | -0.6% | -7.6% | -3.6% | +2.7% | -7.7% | +6.9% |
| Nov 5 | Stifel | Maintains | Buy → Buy | — | $2.89 | $2.50 | -13.5% | -5.9% | +1.5% | -1.4% | -0.7% | +16.7% |
| Aug 20 | Benchmark | Downgrade | Buy → Hold | — | $2.71 | $2.64 | -2.6% | -4.1% | +1.5% | -4.9% | +4.0% | +3.1% |
| Jul 11 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $2.80 | $2.91 | +3.9% | +11.8% | -0.3% | +2.6% | +9.1% | -3.4% |
| May 8 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $4.04 | $4.04 | +0.0% | -5.0% | +2.9% | -3.0% | +0.5% | -0.8% |
| Feb 22 | Benchmark | Upgrade | Hold → Buy | — | $4.81 | $5.03 | +4.6% | +0.8% | +0.4% | +1.6% | +3.4% | -0.8% |
| Feb 21 | Stifel | Maintains | Buy → Buy | — | $5.31 | $5.25 | -1.1% | -9.4% | +0.8% | +0.4% | +1.6% | +3.4% |
| Aug 31 | Benchmark | Maintains | Buy → Buy | — | $5.80 | $5.79 | -0.2% | -6.0% | +2.6% | -0.7% | -0.7% | +0.9% |
| Aug 4 | Goldman Sachs | Maintains | Buy → Buy | — | $6.97 | $6.52 | -6.5% | -13.3% | -3.1% | +0.7% | +2.2% | -2.3% |
| May 5 | Credit Suisse | Maintains | Outperform → Outperform | — | $6.61 | $6.41 | -3.0% | -9.4% | -4.7% | -0.9% | +4.1% | -2.5% |
| Feb 28 | TD Cowen | Maintains | Outperform → Outperform | — | $8.43 | $8.49 | +0.7% | -0.4% | -3.0% | +0.4% | +2.4% | -3.3% |
| Feb 22 | BMO Capital | Maintains | Outperform → Outperform | — | $8.89 | $8.70 | -2.1% | -1.1% | -3.2% | -1.6% | +0.7% | -0.4% |
| Feb 22 | Credit Suisse | Maintains | Outperform → Outperform | — | $8.89 | $8.70 | -2.1% | -1.1% | -3.2% | -1.6% | +0.7% | -0.4% |
| Jan 6 | SVB Leerink | Maintains | Outperform → Outperform | — | $9.65 | $9.70 | +0.5% | -1.5% | +0.4% | -1.8% | +2.3% | +6.2% |
| Dec 15 | Goldman Sachs | Maintains | Buy → Buy | — | $10.13 | $11.14 | +10.0% | +2.7% | -1.8% | -2.6% | +4.7% | +1.8% |
| Nov 16 | Truist | Maintains | Buy → Buy | — | $14.49 | $14.73 | +1.7% | +0.2% | -3.0% | +0.6% | -0.7% | -0.6% |
| Nov 9 | SVB Leerink | Maintains | Outperform → Outperform | — | $12.24 | $12.99 | +6.1% | -3.5% | +9.3% | +5.2% | +5.1% | +1.5% |
| Aug 10 | Credit Suisse | Maintains | Outperform → Outperform | — | $11.11 | $10.72 | -3.5% | +20.1% | +0.1% | +2.4% | -1.0% | -5.8% |
| Jul 26 | Piper Sandler | Maintains | Overweight → Overweight | — | $10.10 | $10.11 | +0.1% | +0.9% | +3.1% | -0.8% | -3.7% | +1.0% |
| May 11 | Piper Sandler | Maintains | Overweight → Overweight | — | $6.64 | $6.96 | +4.8% | -13.9% | +17.3% | +7.7% | +8.0% | +4.4% |
| May 11 | SVB Leerink | Maintains | Outperform → Outperform | — | $6.64 | $6.96 | +4.8% | -13.9% | +17.3% | +7.7% | +8.0% | +4.4% |
| Feb 25 | Credit Suisse | Maintains | Outperform → Outperform | — | $8.45 | $9.36 | +10.8% | +5.7% | -2.5% | +3.8% | +4.3% | -4.1% |
| Feb 25 | SVB Leerink | Maintains | Outperform → Outperform | — | $8.45 | $9.36 | +10.8% | +5.7% | -2.5% | +3.8% | +4.3% | -4.1% |
| Dec 21 | Benchmark | Maintains | Buy → Buy | — | $14.60 | $14.92 | +2.2% | +7.8% | -2.2% | -3.1% | -1.2% | -7.1% |
| Nov 19 | Piper Sandler | Maintains | Overweight → Overweight | — | $15.31 | $15.57 | +1.7% | +3.2% | -8.7% | -3.2% | +3.4% | -3.1% |
| Aug 13 | Credit Suisse | Maintains | Outperform → Outperform | — | $15.19 | $15.00 | -1.3% | +17.8% | -1.3% | -6.1% | +1.0% | -5.7% |
| May 14 | Credit Suisse | Maintains | Outperform → Outperform | — | $34.14 | $31.75 | -7.0% | -7.0% | +7.6% | -3.5% | -1.9% | -1.7% |
| Mar 30 | Stifel | Maintains | Buy → Buy | — | $23.29 | $27.52 | +18.2% | +14.6% | +27.3% | -9.6% | -8.5% | +3.2% |
| Feb 8 | SVB Leerink | Maintains | Outperform → Outperform | — | $46.55 | $49.00 | +5.3% | -3.3% | +4.4% | -0.0% | -2.1% | -6.6% |
| Jan 5 | BMO Capital | Maintains | Outperform → Outperform | — | $39.10 | $38.81 | -0.7% | -1.5% | +2.9% | -0.7% | +1.0% | -7.9% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 14, 2026 | Montalbano John S.Dir | — | Buy | 20,000 | $4.77 | $95K | 241,000 | -2.64% | +1.73% |
8-K · 7.01
! Medium
AbCellera Biologics Inc. -- 8-K 7.01: Regulation FD Disclosure
AbCellera will host an investor call at 4:30 a.m. on August 10, 2026, to discuss Phase 2 results from its ABCL635 clinical trial, providing investors opportunity to assess the candidate's therapeutic progress.
Aug 10
8-K · 8.01
!! High
AbCellera Biologics Inc. -- 8-K 8.01: Material Event / Announcement
Aug 7
8-K · 2.02
!! High
AbCellera Biologics Inc. -- 8-K 2.02: Earnings Results
Aug 5
8-K · 8.01
!! High
AbCellera Biologics Inc. -- 8-K 8.01: Material Event / Announcement
Jul 29
8-K · 5.02
!!! Very High
AbCellera Biologics Inc. -- 8-K 5.02: Executive Change
Lynn Seely's appointment as Class III director at AbCellera strengthens board governance, potentially signaling confidence in management continuity and strategic direction execution.
Jul 6
8-K · 8.01
!! High
AbCellera Biologics Inc. -- 8-K 8.01: Material Event / Announcement
AbCellera partnered with Jazz Pharmaceuticals to develop antibody candidates for gastrointestinal cancers and solid tumors, combining AbCellera's discovery platform with Jazz's development expertise.
Jun 17
8-K
AbCellera Biologics Inc. -- 8-K Filing
Jun 12
8-K · 5.02
!!! Very High
AbCellera Biologics Inc. -- 8-K 5.02: Executive Change
Jun 5
8-K · 2.02
!! High
AbCellera Biologics Inc. -- 8-K 2.02: Earnings Results
May 11
8-K · 7.01
! Medium
AbCellera Biologics Inc. Common Shares -- 8-K 7.01: Regulation FD Disclosure
AbCellera will present 2025 financial results and corporate updates during its February 24, 2026 earnings call using a prepared presentation.
Feb 24
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Two Sigma Investments, Lp | 10,437,431 | $82M | Reduced | Jun 2026 |
| 2 | Td Waterhouse Canada Inc. | 9,568,149 | $73M | — | Jun 2026 |
| 3 | Capital World Investors | 13,361,096 | $47M | — | Mar 2026 |
| 4 | Blackrock, Inc. | 3,805,309 | $30M | New | Jun 2026 |
| 5 | Citadel Advisors Llc | 3,173,024 | $25M | Added | Jun 2026 |
| 6 | Morgan Stanley | 6,003,700 | $21M | Added | Dec 2025 |
| 7 | Tudor Investment Corp Et Al | 2,063,191 | $16M | Reduced | Jun 2026 |
| 8 | Ubs Group Ag | 4,209,052 | $15M | Added | Mar 2026 |
| 9 | Bank Of America Corp /de/ | 2,999,936 | $10M | Added | Mar 2026 |
| 10 | Alyeska Investment Group, L.p. | 2,592,105 | $9M | New | Mar 2026 |
| 11 | Renaissance Technologies Llc | 990,929 | $8M | Reduced | Jun 2026 |
| 12 | Guardian Partners Inc. | 1,786,415 | $6M | New | Mar 2026 |
| 13 | Jane Street Group, Llc | 1,397,088 | $5M | Added | Dec 2025 |
| 14 | Intellectus Partners, Llc | 551,583 | $4M | Added | Jun 2026 |
| 15 | Hrt Financial Lp | 1,235,153 | $4M | Added | Mar 2026 |
| 16 | Millennium Management Llc | 518,571 | $4M | Reduced | Jun 2026 |
| 17 | Bank Of Montreal /can/ | 482,799 | $4M | Added | Jun 2026 |
| 18 | Decker Retirement Planning Inc. | 336,112 | $3M | New | Jun 2026 |
| 19 | Susquehanna International Group, Llp | 750,393 | $3M | Reduced | Mar 2026 |
| 20 | Daiwa Securities Group Inc. | 311,500 | $2M | New | Jun 2026 |
Mutual Funds / ETFs (N-PORT) — Top 17
All ↗
Valuation
Market Cap
$3.80B
Enterprise Value
$3.24B
P/E (TTM)
-23.57x
Forward P/E
—
PEG Ratio
0.64x
P/B
3.33x
P/S
57.46x
P/FCF
-21.85x
EV/EBITDA
—
Shares Out
298.7M
Financials (TTM)
Revenue
$66.2M
Net Income
-$164.7M
EBITDA
-$160.3M
Free Cash Flow
-$174.1M
Op Cash Flow
-$131.3M
EPS Basic
$-0.49
EPS Diluted
$-0.54
EPS Forward
$-0.66
Gross Margin
75.0%
Op Margin
-340.2%
Net Margin
-248.8%
Balance Sheet
Total Assets
$1.36B
Total Liab.
$215.6M
Total Equity
$1.14B
Cash
$560.3M
LT Debt
$0
Book Value/Sh
$3.82
Debt/Equity
0.13x
Current Ratio
11.32
Quick Ratio
11.23
Returns & Growth
ROE
-15.1%
ROA
-10.8%
ROIC
-13.8%
Rev Growth YoY
+160.6%
EPS Growth YoY
+10.9%
Price Returns
2W
+3.5%
1M
+4.2%
3M
+114.5%
6M
+228.7%
12M
+155.4%
Technicals
52W High
$12.73
52W Low
$2.78
50d MA
$9.00
200d MA
$5.45
RSI (14)
53.30
ATR (14)
$0.67
Beta
0.85
Avg Volume
8.3M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$20.17
High
$34.00
Low
$5.00
Median
$23.50
Data updated apr 24, 2026 10:12am
· Source: financialmodelingprep.com